ライフサイエンスコーパス: dextromethorphan

1 - clonidine and opioids; third, nystagmus - dextromethorphan.

2 preparations, particularly those containing dextromethorphan.

3 tors: mecamylamine, ketamine, bupropion, and dextromethorphan.

4 ioids, antidepressants, and the antitussive, dextromethorphan.

5 01 with METH (0.1-100 microM) did not reduce dextromethorphan (1 mM)-displaceable ligand binding.

6 The NMDA receptor blocker dextromethorphan (150 mg) suppressed the reduction in IC

7 old for SN; 20 mg/kg no effect) and 40 mg/kg dextromethorphan (3.4-fold for CS, 6.2-fold for SN, in 6

8 elective and competitive NMDA antagonist, or dextromethorphan (5-15 mg/kg, s.c.), a noncompetitive NM

9 dent plasticity was reduced substantially by dextromethorphan (an N-methyl-d-aspartate receptor block

10 Dextromethorphan, an antitussive agent with NMDA recepto

11 articipants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish ba

12 The present study investigated the effect of dextromethorphan and 6,7-dinitroquinoxaline-2,3-dione (D

13 All individuals were also given liquid dextromethorphan and albuterol inhaler with a spacer.

14 capture and release of two guest molecules, dextromethorphan and beta-estradiol, which are widely fo

15 ptake inhibitors, and a new agent containing dextromethorphan and quinidine.

16 The NMDA antagonist dextromethorphan and the non-NMDA (AMPA/kainate) antagon

17 by the noncompetitive antagonists MK-801 and dextromethorphan and were dependent on extracellular cal

18 enzymes (caffeine, tolbutamide, omeprazole, dextromethorphan, and oral and intravenous midazolam) wa

19 ate (NMDA) receptor (e.g., ketamine, MK-801, dextromethorphan, and phencyclidine) produce analgesia b

20 end of abuse of certain preparations such as dextromethorphan, and specific cases of morbidity and ev

21 Two such agents, memantine and dextromethorphan, are already in widespread clinical use

22 cations is demonstrated in this report using dextromethorphan as a model compound.

23 significantly reduced by pre-treatment with dextromethorphan but not DNQX.

24 Neither LY 2359595 nor dextromethorphan by itself significantly altered body te

25 Dextromethorphan causes alterations in mental status tha

26 The recent trend of prescription and dextromethorphan-containing over-the-counter medication

27 enzyloxy-4-trifluoromethylcoumarin (BFC) and dextromethorphan (DEX).

28 ABA(A) receptor agonist) relative to that of dextromethorphan (DM) (an NMDA receptor antagonist) and

29 d the neuroprotective property of analogs of dextromethorphan (DM) in lipopolysaccharide (LPS) and 1-

30 ersus combined treatment of melatonin and/or dextromethorphan (DM), a clinically available N-methyl-d

31 sly showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used

32 We recently reported that dextromethorphan (DM), a widely used anti-tussive agent,

33 We recently reported that dextromethorphan (DM), an active ingredient in a variety

34 noticed that, in vivo, the NMDAR antagonist dextromethorphan (DXM) enhanced glucose tolerance in mic

35 sult of NMDA receptor antagonism with 120 mg dextromethorphan [F(1,34) = 5.291, P = 0.028].

36 -1), with a relative order of mecamylamine > dextromethorphan > or = ketamine > bupropion.

37 lues determined in this study indicated that dextromethorphan-induced inhibition should produce a lon

38 Pharmacodynamic interactions with dextromethorphan may produce serotonin syndrome.

39 found to metabolize xenobiotics carrying out dextromethorphan O- and N-demethylations, diclofenac 4'-

40 The primary effect of dextromethorphan, (+)-pentazocine, (+)-cyclazocine, (+)-

41 response and rerandomized in a 1:1 ratio to dextromethorphan-quinidine (n = 59) or placebo (n = 60).

42 ts were randomized in a 3:4 ratio to receive dextromethorphan-quinidine (n = 93) or placebo (n = 127)

43 lel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo duri

44 ion scores were reduced from 5.8 to 3.8 with dextromethorphan-quinidine and from 6.7 to 5.8 with plac

45 ion scores were reduced from 7.1 to 3.8 with dextromethorphan-quinidine and from 7.0 to 5.3 with plac

46 In stage 2, patients receiving dextromethorphan-quinidine continued; those receiving pl

47 with probable Alzheimer disease, combination dextromethorphan-quinidine demonstrated clinically relev

48 Adverse events included falls (8.6% for dextromethorphan-quinidine vs 3.9% for placebo), diarrhe

49 Serious adverse events occurred in 7.9% with dextromethorphan-quinidine vs 4.7% with placebo.

50 reduced NPI Agitation/Aggression scores for dextromethorphan-quinidine vs placebo (ordinary least sq

51 Dextromethorphan-quinidine was not associated with cogni

52 In vivo, MK-801 and dextromethorphan reduce methamphetamine-induced activati

53 hereas the PCP-related sigma ligands such as dextromethorphan, (+)-SKF10047 and (+)-cyclazocine were

54 The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at

55 ults indicate that the ability of MK-801 and dextromethorphan to protect against methamphetamine neur

56 not significantly affected, whereas block by dextromethorphan was increased (N615K [n=9], 56% [8] vs

57 Using pcSFC and MS/MS, dextromethorphan was quantified in 96-well plates at a r

58 The non-opioid antitussive, dextromethorphan, which has been shown to inhibit glutam